Ensitrelvir Reduces COVID-19 Incidence by 6.1% in Household Contacts

Mitigating Household COVID-19 Transmission

Despite the availability of vaccines and treatments for established coronavirus disease 2019 (COVID-19), preventing transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within households remains a persistent clinical challenge. Oral antiviral agents that inhibit viral replication, such as 3C-like protease inhibitors, have proven effective for treating mild-to-moderate illness by reducing viral load and symptom duration [1, 2, 3, 4]. While some agents reduce hospitalization and death in infected patients [5], a significant gap has existed regarding their use for postexposure prophylaxis [6, 7]. A recent randomized controlled trial now provides evidence on the efficacy of the oral antiviral ensitrelvir for preventing COVID-19 in household contacts of infected individuals.

Ensitrelvir's Mechanism and Prior Use

The agent under investigation, ensitrelvir, is an oral inhibitor of the SARS-CoV-2 3C-like protease. This enzyme functions as a molecular scissor, cleaving viral polyproteins into functional units essential for viral replication. By blocking this critical step, ensitrelvir effectively halts the virus's life cycle. Based on this mechanism, the drug is already approved in Japan for treating mild-to-moderate COVID-19. However, its potential role in prevention had been undefined. Prior to this study, no antiviral agents were approved specifically for postexposure prophylaxis in household contacts of patients with COVID-19, leaving a critical unmet need for strategies to protect those at highest risk of infection due to prolonged, close contact.

Trial Design and Participant Characteristics

To assess ensitrelvir's prophylactic potential, investigators conducted a double-blind, randomized, placebo-controlled trial, the gold standard for evaluating clinical interventions. The study enrolled household contacts of a person with recently diagnosed COVID-19 (the index patient). Eligible participants, who themselves tested negative for SARS-CoV-2 at baseline, were randomly assigned to receive either ensitrelvir or a placebo within 72 hours of the index patient's symptom onset. The ensitrelvir regimen consisted of a loading dose of 375 mg on day 1, followed by 125 mg daily on days 2 through 5. The study's modified intention-to-treat population included 1030 participants in the ensitrelvir group and 1011 in the placebo group.

The primary endpoint was the development of COVID-19 by day 10, defined as a central laboratory-confirmed positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test plus the presence of at least one of 14 prespecified COVID-19 symptoms lasting 48 hours or more. The participant cohort was representative of a general adult population, with a mean age of 42.4 years. The intervention was timely, as 71.1% of participants were randomized within 48 hours of the index patient's symptoms. Notably, 37.0% of participants had at least one risk factor for severe COVID-19, making the findings relevant to more vulnerable populations.

Significant Reduction in COVID-19 Incidence

The trial's primary analysis demonstrated a substantial protective effect for ensitrelvir. The incidence of symptomatic, laboratory-confirmed COVID-19 was significantly lower in the group receiving the antiviral. By day 10, the incidence of COVID-19 was 2.9% in the ensitrelvir group compared to 9.0% in the placebo group. This finding corresponds to a risk ratio of 0.33 (95% confidence interval [CI], 0.22 to 0.49; P<0.001), indicating that household contacts who received ensitrelvir had their risk of developing COVID-19 reduced by 67% compared to those who received placebo. From a clinical perspective, this represents an absolute risk reduction of 6.1 percentage points, suggesting that approximately 16 household contacts would need to be treated with ensitrelvir to prevent one case of COVID-19.

Safety Profile and Clinical Outcomes

The efficacy of ensitrelvir as postexposure prophylaxis was complemented by a reassuring safety profile. The overall incidence of adverse events during the trial was nearly identical between the two arms: 15.1% in the ensitrelvir group and 15.5% in the placebo group. This similarity suggests the drug was well tolerated and did not contribute a significant burden of side effects. Furthermore, the rate of serious adverse events was low and equivalent in both groups, occurring in 0.2% of participants in the ensitrelvir arm and 0.2% in the placebo arm. Critically for patient outcomes, the researchers reported no COVID-19-related hospitalizations or deaths in either group during the study period. These data indicate that the prophylactic regimen's benefits were not offset by an increased risk of adverse events.

Clinical Implications and Study Context

The results of this trial provide strong evidence that ensitrelvir, when administered to household contacts within 72 hours of an index patient's symptom onset, is effective for preventing COVID-19. For practicing clinicians, this offers a potential strategy to reduce secondary transmission in a high-risk setting. The combination of a two-thirds reduction in infection risk and a safety profile comparable to placebo positions ensitrelvir as a viable option for postexposure prophylaxis, should it receive regulatory approval for this indication. The study was funded by Shionogi, the drug's developer, and is registered in the Japan Registry for Clinical Trials (jRCT2031230124) and at ClinicalTrials.gov (NCT05897541), ensuring transparency of the trial protocol and results.

References

1. Khorramnia S, Moghadam SHP, Sarkoohi A, et al. Ensitrelvir for the treatment of COVID-19: A systematic review of evidence.. Japanese journal of infectious diseases. 2025. doi:10.7883/yoken.JJID.2024.372

2. Yotsuyanagi H, Ohmagari N, Doi Y, et al. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. medRxiv. 2023. doi:10.1101/2023.07.11.23292264

3. Mukae H, Yotsuyanagi H, Ohmagari N, et al. Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review.. Therapeutic advances in infectious disease. 2025. doi:10.1177/20499361251321724

4. Brüssow H. Antivirals Targeting Coronavirus RNA ‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID ‐19 Clinical Trials. Microbial Biotechnology. 2026. doi:10.1111/1751-7915.70342

5. Schilling WH, Jittamala P, Watson JA, et al. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. The Lancet Infectious Diseases. 2023. doi:10.1016/s1473-3099(23)00493-0

6. Singh S, Boyd S, Schilling WH, Watson JA, Mukaka M, White NJ. The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae045

7. Wongnak P, Schilling WH, Jittamala P, et al. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV). The Lancet Infectious Diseases. 2024. doi:10.1016/s1473-3099(24)00183-x